Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia
Introduction: Patients referred to as having thalassemia major are usually those who come to medical attention in the first year of life and subsequently require regular transfusions to survive. Those who present later or who seldom need transfusions are said to have thalassemia intermediaHydroxyure...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2012-10-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/344/385 |
_version_ | 1797765331872120832 |
---|---|
author | Ali Ghasemi Bijan Keikhaei Saghi Elmi |
author_facet | Ali Ghasemi Bijan Keikhaei Saghi Elmi |
author_sort | Ali Ghasemi |
collection | DOAJ |
description | Introduction: Patients referred to as having thalassemia major are usually those who come to medical attention in the first year of life and subsequently require regular transfusions to survive. Those who present later or who seldom need transfusions are said to have thalassemia intermediaHydroxyurea, an s-phase-specific and non-DNA-hypomethylating chemotherapeutic agents is capable of inducing HbF synthesis.Patients & Methods: The study evaluated hydroxyurea complications in a cohort of 28 patients with major (n=20) and intermediate thalassemia (n=8). HU was started in a dose of 10 mg/kg daily and then increased by 5 mg/kg daily every 4-6 weeks until toxicity occurred or clinical response was achieved.Results: We reviewed the records of 28 patients with intermediate and major b-thalassemia. The statistical analysis did not show a significant correlation between age at diagnosis, age of starting HU, duration of HU treatment, dose of HU and ethnicity.Side effects of HU have been recorded in 21 (75%) patients.Adverse effects were hair loss (n=8; 28.57%), hyper pigmentation (n=4; 14.28%), nausea and vomiting (n=2; 7.14%), abdominal pain (n=4; 14.28%), and increase in hepatic enzymes (n=2; 7.14%).Neurologic complications were headache (n=7; 25%), vertigo (n=1; 3.57%) and drowsiness (n=1; 3.57%).Conclusion: According to the results of this and other studies, it seems that HU therapy in thalassemic patients can be safely used but can be started at low doses and increased slowly , monitoring the patient's response |
first_indexed | 2024-03-12T20:09:41Z |
format | Article |
id | doaj.art-6877762eddfe4b57b48bd09c40a4aac7 |
institution | Directory Open Access Journal |
issn | 2008-3009 2008-2207 |
language | English |
last_indexed | 2024-03-12T20:09:41Z |
publishDate | 2012-10-01 |
publisher | Tehran University of Medical Sciences |
record_format | Article |
series | International Journal of Hematology-Oncology and Stem Cell Research |
spelling | doaj.art-6877762eddfe4b57b48bd09c40a4aac72023-08-02T01:51:44ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072012-10-01641113Side Effects of Hydroxyurea in Patients with Major and Intermediat B-ThalassemiaAli GhasemiBijan KeikhaeiSaghi ElmiIntroduction: Patients referred to as having thalassemia major are usually those who come to medical attention in the first year of life and subsequently require regular transfusions to survive. Those who present later or who seldom need transfusions are said to have thalassemia intermediaHydroxyurea, an s-phase-specific and non-DNA-hypomethylating chemotherapeutic agents is capable of inducing HbF synthesis.Patients & Methods: The study evaluated hydroxyurea complications in a cohort of 28 patients with major (n=20) and intermediate thalassemia (n=8). HU was started in a dose of 10 mg/kg daily and then increased by 5 mg/kg daily every 4-6 weeks until toxicity occurred or clinical response was achieved.Results: We reviewed the records of 28 patients with intermediate and major b-thalassemia. The statistical analysis did not show a significant correlation between age at diagnosis, age of starting HU, duration of HU treatment, dose of HU and ethnicity.Side effects of HU have been recorded in 21 (75%) patients.Adverse effects were hair loss (n=8; 28.57%), hyper pigmentation (n=4; 14.28%), nausea and vomiting (n=2; 7.14%), abdominal pain (n=4; 14.28%), and increase in hepatic enzymes (n=2; 7.14%).Neurologic complications were headache (n=7; 25%), vertigo (n=1; 3.57%) and drowsiness (n=1; 3.57%).Conclusion: According to the results of this and other studies, it seems that HU therapy in thalassemic patients can be safely used but can be started at low doses and increased slowly , monitoring the patient's responsehttp://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/344/385Side EffectsHydroxyureaB-Thalassemia |
spellingShingle | Ali Ghasemi Bijan Keikhaei Saghi Elmi Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia International Journal of Hematology-Oncology and Stem Cell Research Side Effects Hydroxyurea B-Thalassemia |
title | Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia |
title_full | Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia |
title_fullStr | Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia |
title_full_unstemmed | Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia |
title_short | Side Effects of Hydroxyurea in Patients with Major and Intermediat B-Thalassemia |
title_sort | side effects of hydroxyurea in patients with major and intermediat b thalassemia |
topic | Side Effects Hydroxyurea B-Thalassemia |
url | http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/344/385 |
work_keys_str_mv | AT alighasemi sideeffectsofhydroxyureainpatientswithmajorandintermediatbthalassemia AT bijankeikhaei sideeffectsofhydroxyureainpatientswithmajorandintermediatbthalassemia AT saghielmi sideeffectsofhydroxyureainpatientswithmajorandintermediatbthalassemia |